Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.57 |
| ▸ | PPARA | Q07869 | 20/20 | 0.57 |
| ▸ | PPARG | P37231 | 18/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007594 | 0.91 | PPARD (0.47) | PPARDPPARAPPARG | |
| SCHEMBL30007652 | 0.88 | PPARD (0.56) | PPARDPPARAPPARG | |
| SCHEMBL3511782 | 0.87 | PPARD (0.54) | PPARDPPARAPPARG | |
| SCHEMBL30007517 | 0.86 | PPARA (0.55) | PPARDPPARAPPARG | |
| SCHEMBL3509000 | 0.85 | PPARD (0.49) | PPARDPPARAPPARG | |
| SCHEMBL2030587 | 0.84 | PPARA (0.51) | PPARDPPARAPPARG | |
| SCHEMBL3512170 | 0.82 | PPARD (0.46) | PPARDPPARAPPARG | |
| SCHEMBL1935430 | 0.78 | PPARA (0.55) | PPARDPPARAPPARG | |
| SCHEMBL3510970 | 0.76 | PPARA (0.51) | PPARDPPARAPPARG | |
| SCHEMBL3510967 | 0.76 | PPARA (0.51) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2024-07-04 | — | — | US | claimed |
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2024-07-04 | — | — | US | claimed |
| EP-4337185-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | Genfit (FR) | 2024-03-20 | — | — | EP | claimed |
| EP-4337184-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2024-03-20 | — | — | EP | claimed |
| WO-2022238448-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2022-11-17 | — | — | WO | claimed |
| WO-2022238445-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2022-11-17 | — | — | WO | claimed |
| EP-2046716-B1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2013-08-14 | — | — | EP | claimed |
| US-8188148-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-05-29 | — | — | US | claimed |
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4337184-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337185-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | Genfit (FR) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022238445-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022238448-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2022-11-17 | — | — | WO | disclosed |
| US-8188148-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188148-B2 | Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | disclosed |
| WO-2007147880-A1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | PPARA, PPARD, FABP1 | PPARD 2/4885PPARA 1/4885PPARG 4/4885 |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP8, DPP4 | PPARD 9/4885PPARA 11/4885PPARG 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.